HC Wainwright & Co. Maintains Buy on Edgewise Therapeutics, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Positive 84.3%

Neg 0% Neu 0% Pos 84.3%

HC Wainwright & Co. analyst Lander Egaña Gorroño maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Buy and raises the price target from $42 to $45.